San Francisco-based Hyperion Therapeutics has raised a whopping $60 million in a Series C financing round. New investors Bay City Capital and Panorama Capital co-led the financing, while existing investors Highland Capital Partners, NEA, and Sofinnova Ventures also participated.
Hyperion recently announced positive Phase II results and an orphan drug designation for HPN-100, a potential treatment for urea cycle disorders (UCT). This new round of funding will help fund Phase III trials of the drug for UCT, as well as a Phase II study in low grade hepatic encephalopathy.
"Considerable unmet needs remain in the treatment of both urea cycle disorders and hepatic encephalopathy," said Daniel Perez of Bay City Capital. "We believe the Hyperion management team, with their extensive drug development and regulatory expertise, is well positioned to lead a clinical development program focused on potential treatment options for these
- here's Hyperion's release [1]
Related Article:
Hyperion garners $40M in second VC round [2]
Links:
[1] http://www.fiercebiotech.com/press-releases/hyperion-therapeutics-raises-60-million-series-c
[2] http://www.fiercebiotech.com/story/hyperion-garners-40m-second-vc-round/2007-09-05